menu
    • menu
    [{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Monalizumab","moa":"||NKG2A","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pharma \/ AstraZeneca"}]

    Find Clinical Drug Pipeline Developments & Deals for Monalizumab

    Menu

    Monalizumab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Innate Pharma

                            France arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monalizumab,Durvalumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $450.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment Fro...

                            Details : Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells.

                            Product Name : IPH2201

                            Product Type : Antibody

                            Upfront Cash : $250.0 million

                            April 29, 2022

                            Lead Product(s) : Monalizumab,Durvalumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $450.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Innate Pharma

                            France arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monalizumab,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

                            Details : Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.

                            Product Name : IPH2201

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 08, 2022

                            Lead Product(s) : Monalizumab,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Innate Pharma

                            France arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monalizumab,Durvalumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Monalizumab Data from COAST Trial Presented at ESMO Congress 2021

                            Details : Results of the interim analysis showed monalizumab in combination with durvalumab improved progression-free survival (PFS) and objective response rate (ORR) compared to durvalumab alone in patients with unresectable, Stage III non-small cell lung cancer ...

                            Product Name : IPH2201

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 17, 2021

                            Lead Product(s) : Monalizumab,Durvalumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Innate Pharma

                            France arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monalizumab,Cetuximab,Durvalumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress

                            Details : Innate to present new Phase 2 data on the combination of IPH2201 (monalizumab), a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells.

                            Product Name : IPH2201

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 12, 2021

                            Lead Product(s) : Monalizumab,Cetuximab,Durvalumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Innate Pharma

                            France arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monalizumab,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $50.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50 M Payment from Astrazeneca

                            Details : Monalizumab, Innate’s lead partnered asset. On April 24, 2015, Innate signed a co development and commercialization agreement with AstraZeneca to accelerate and broaden the development of monalizumab.

                            Product Name : IPH2201

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            October 23, 2020

                            Lead Product(s) : Monalizumab,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : $50.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Innate Pharma

                            France arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Innate Pharma

                            France arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monalizumab,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innate Pharma to Present New Efficacy Data for Monalizumab in Combination with Cetuximab in Head and Neck canc...

                            Details : Darolutamide significantly reduced risk of death by 31% in men with non-metastatic castration-resistant prostate cancer (nmCRPC) and delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic s...

                            Product Name : IPH2201

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 14, 2020

                            Lead Product(s) : Monalizumab,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth